- Home
- KAVL vs AYTU Comparison
KAVL vs AYTU Comparison
Compare KAVL & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- AYTU
- Stock Information
- Founded
- KAVL 1998
- AYTU N/A
- Country
- KAVL United States
- AYTU United States
- Employees
- KAVL N/A
- AYTU N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- KAVL Health Care
- AYTU Health Care
- Exchange
- KAVL Nasdaq
- AYTU Nasdaq
- Market Cap
- KAVL 7.9M
- AYTU 8.3M
- IPO Year
- KAVL N/A
- AYTU N/A
- Fundamental
- Price
- KAVL $0.49
- AYTU $1.05
- Analyst Decision
- KAVL
- AYTU
- Analyst Count
- KAVL 0
- AYTU 0
- Target Price
- KAVL N/A
- AYTU N/A
- AVG Volume (30 Days)
- KAVL 47.0K
- AYTU 31.3K
- Earning Date
- KAVL 06-17-2025
- AYTU 05-14-2025
- Dividend Yield
- KAVL N/A
- AYTU N/A
- EPS Growth
- KAVL N/A
- AYTU N/A
- EPS
- KAVL N/A
- AYTU N/A
- Revenue
- KAVL $3,877,695.00
- AYTU $77,232,000.00
- Revenue This Year
- KAVL N/A
- AYTU N/A
- Revenue Next Year
- KAVL N/A
- AYTU $8.14
- P/E Ratio
- KAVL N/A
- AYTU N/A
- Revenue Growth
- KAVL N/A
- AYTU N/A
- 52 Week Low
- KAVL $0.46
- AYTU $0.95
- 52 Week High
- KAVL $8.37
- AYTU $3.45
- Technical
- Relative Strength Index (RSI)
- KAVL 35.40
- AYTU 41.21
- Support Level
- KAVL $0.47
- AYTU $0.99
- Resistance Level
- KAVL $0.51
- AYTU $1.10
- Average True Range (ATR)
- KAVL 0.03
- AYTU 0.08
- MACD
- KAVL 0.01
- AYTU 0.01
- Stochastic Oscillator
- KAVL 31.25
- AYTU 55.56
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.